Breast Cancer clinical trials in Montana

7 actively recruiting breast cancer trials at 9 sites across Montana.

Data from ClinicalTrials.gov · last refreshed 2026-10-12

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology

NCT ID: NCT05879926

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Saint Vincent Frontier Cancer Center — Billings, Montana
Intermountain Health West End Clinic — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Network

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…

Sponsor: SWOG Cancer Research Network

NCT ID: NCT05929768

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Saint Vincent Frontier Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Saint James Community Hospital and Cancer Treatment Center — Butte, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT06058377

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Community Medical Center — Missoula, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting NIH

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer ret…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT07391774

Sites in Montana:

Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Community Medical Center — Missoula, Montana

View on ClinicalTrials.gov →

Phase 3 Recruiting Industry

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast …

Sponsor: Celcuity Inc

NCT ID: NCT06757634

Sites in Montana:

SCL Health - Cancer Centers of Montana — Billings, Montana

View on ClinicalTrials.gov →

Phase 2 Recruiting NIH

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…

Sponsor: National Cancer Institute (NCI)

NCT ID: NCT05564377

Sites in Montana:

Community Hospital of Anaconda — Anaconda, Montana
Billings Clinic Cancer Center — Billings, Montana
Bozeman Health Deaconess Hospital — Bozeman, Montana
Benefis Sletten Cancer Institute — Great Falls, Montana
Logan Health Medical Center — Kalispell, Montana

View on ClinicalTrials.gov →

Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.

NCT ID: NCT03452774

Sites in Montana:

Massive Bio SYNERGY-AI site — Billings, Montana

View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12